Back to top
more

Coherus Oncology, Inc. (CHRS)

(Real Time Quote from BATS)

$1.69 USD

1.69
585,363

+0.02 (1.20%)

Updated Apr 8, 2026 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for CHRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Coherus Oncology, Inc. [CHRS]

Reports for Purchase

Showing records 1 - 20 ( 91 total )

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/08/2026

Industry Report

Pages: 11

Doug's Weekly Dose

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/02/2026

Industry Report

Pages: 9

Doug's Weekly Dose

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/08/2026

Industry Report

Pages: 8

Doug's Weekly Dose: Week of 2/6/26

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/05/2026

Daily Note

Pages: 3

Three Reasons This JNJ Clinical Collaboration Shouldn't be Overlooked; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

02/02/2026

Industry Report

Pages: 8

Doug''s Weekly Dose

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

01/16/2026

Industry Report

Pages: 5

Takeaways from Our Coverage at Day Three of the JPM Healthcare Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/14/2025

Daily Note

Pages: 18

Doug?s Weekly Dose: Week of 11/14/2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/07/2025

Company Report

Pages: 5

Strong Demand for Loqtorzi Drives Revenue Growth; Data-Rich 2026; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/11/2025

Industry Report

Pages: 6

Takeaways From Our Coverage At Day Three of the H.C. Wainwright Global Investment Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/08/2025

Company Report

Pages: 5

Loqtorzi Offers Signs of Momentum as Community Use and Label Expansion Provide Future Growth Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/21/2025

Daily Note

Pages: 6

19 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/13/2025

Company Report

Pages: 5

Patience Will be Needed for Loqtorzi; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

04/29/2025

Daily Note

Pages: 4

Early Phase 1 Data Demonstrated Potential Efficacy of CHS-144/Toripalimab To Overcome PD-1 Resistance

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/11/2025

Company Report

Pages: 5

Funding in Place to Cover Key Catalysts Through 2026; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

01/23/2025

Daily Note

Pages: 3

Final Data From Casdozo in Triplet Combo Therapy Provides Validation for MOA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

12/04/2024

Company Report

Pages: 5

Coherus Divests Udenyca, Finalizing Its Metamorphosis Into an IO Company; Adjust PT to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/01/2024

Industry Report

Pages: 20

The Wedbush Monthly Check-Up: December 2024

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/07/2024

Company Report

Pages: 5

Udenyca Flexes Some Muscle in 3Q and We Expect It Will Do So Again in 2025 After a Short Break; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/16/2024

Company Report

Pages: 4

Printer Woes Lead to Brief Supply Disruption for Udenyca

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

08/09/2024

Company Report

Pages: 5

Udenyca Recover Moves Coherus Forward to Profitability; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party